Proteome Sciences plc
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more
Market Cap & Net Worth: Proteome Sciences plc (PMSNF)
Proteome Sciences plc (PINK:PMSNF) has a market capitalization of $10.52 Million ($10.52 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #30872 globally and #10168 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Proteome Sciences plc's stock price $0.03 by its total outstanding shares 350724912 (350.72 Million).
Proteome Sciences plc Market Cap History: 2015 to 2025
Proteome Sciences plc's market capitalization history from 2015 to 2025. Data shows change from $73.30 Million to $10.52 Million (-18.06% CAGR).
Proteome Sciences plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Proteome Sciences plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.44x
Proteome Sciences plc's market cap is 1.44 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $73.30 Million | $19.64 Billion | -$2.72 Million | 0.00x | N/A |
| 2016 | $13.33 Million | $19.82 Billion | -$2.28 Million | 0.00x | N/A |
| 2017 | $12.91 Million | $18.93 Billion | -$2.50 Million | 0.00x | N/A |
| 2018 | $9.12 Million | $19.67 Billion | -$1.31 Million | 0.00x | N/A |
| 2019 | $8.24 Million | $19.73 Billion | $149.00K | 0.00x | 55.32x |
| 2020 | $14.03 Million | $16.95 Billion | $295.00K | 0.00x | 47.56x |
| 2021 | $24.55 Million | $22.59 Billion | $72.00K | 0.00x | 340.98x |
| 2022 | $17.54 Million | $23.74 Billion | $1.32 Million | 0.00x | 13.23x |
| 2023 | $10.52 Million | $5.03 Million | -$2.44 Million | 2.09x | N/A |
| 2024 | $7.01 Million | $4.89 Million | -$3.41 Million | 1.44x | N/A |
Competitor Companies of PMSNF by Market Capitalization
Companies near Proteome Sciences plc in the global market cap rankings as of March 18, 2026.
Key companies related to Proteome Sciences plc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Proteome Sciences plc Historical Marketcap From 2015 to 2025
Between 2015 and today, Proteome Sciences plc's market cap moved from $73.30 Million to $ 10.52 Million, with a yearly change of -18.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $10.52 Million | +50.00% |
| 2024 | $7.01 Million | -33.33% |
| 2023 | $10.52 Million | -40.00% |
| 2022 | $17.54 Million | -28.57% |
| 2021 | $24.55 Million | +75.00% |
| 2020 | $14.03 Million | +70.21% |
| 2019 | $8.24 Million | -9.62% |
| 2018 | $9.12 Million | -29.35% |
| 2017 | $12.91 Million | -3.16% |
| 2016 | $13.33 Million | -81.82% |
| 2015 | $73.30 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Proteome Sciences plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.52 Million USD |
| MoneyControl | $10.52 Million USD |
| MarketWatch | $10.52 Million USD |
| marketcap.company | $10.52 Million USD |
| Reuters | $10.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.